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This finding was very similar to the 34% reduction in peak CK seen in 
patients with preinfarction angina in the study of Anzai er al. 
In conclusion, published reports remain conflicting as to whether 
prcinfarction angina is associated with improved clinical outcome. The 
protective effect suggested by thz study of Anzai et al. may be real. or 
it may simply refkxt a higher use of aspirin. Further multivariatc 
analysis is needed to clarity this isue. 
Refemmes 
Barron and Viskin suggested that the beneticial effect of przinfarclion 
angina in our study (I) might be caused by the higher in.zideoce of 
aspirin use in patients with that. without preinfar&tion angina, refe;ring 
to the recent findmgs that previous aspirin use was associated with a 
shifttowardalesssevereclinical~ltawnewiththanwithoutaspirinu~ 
in patients with acute coronary syndrome (2). We agree with the 
amccpt itself that prior use of aspirin diminishes the wverity of acute 
ischemic syndrome. 
However, :hcrc was actually no difference in aspirin use bcfore 
infarction between patients with and without preinfarction angma in 
our study (5 [3W] of 148 vs. 5 IS%] of %), Our studj population are 
quite different from those reported by Garcia-Dorado et al. (2). We 
limited the study population to patients with first 0 wave mFardial 
infarction in contrast to the stu& of Garcia-Dorado et al. (2). which 
included a broad spectrum of patients with non-Q wave myocardial 
infar&m as well as &stable angina. Two explanations arc pcrsible for 
the fact that the iocidencz of prior use of antipiatelet agents was 
unexpectedly low in our studyz i) A large portion of the study 
population had a history of angina < 1 month before infarction. More 
precisely, 55’76 of the patients with preinfardion angina had primary 
unstable angina tha! had developed within I Fk of infarct&n (I). In 
such casz+ it seems to be ditlicult to initiate rherapy, including 
antiplatelet agents, before the onset of myncardial infarction. ‘&ii is in 
amtmst to patients with a prior infarction or non-Q wave infarction 
wha havt a bttgstandii histoty of effort aegitm &c&d with anti- 
platelet agents. 2) As Garcia-Dora&? et al pointed out, patients uith 
The optimal management rtratep for inldnt\ Ullh wprd*entrruiar 
tachycardii is a contrcnersial wbjecz in @IL! ti card&@. The 
recent article in the ,wmal b O’SuIl?.~an er al. t 1 I’ p&d a new 
approach using flecainide for the prevention of rccurrcncc of w 
praventricular txhycardia m mfaq. However, in thee ~IXX&XI. the 
authors misrepresented data m a paper from our irtsutution wnczm- 
ing the use of catheter ablation for mcdiity rcfrzt* .supraventti- 
uiar tacwi in infamy. The authors state that “medica@ refrac- 
tory- uchycardii is often cited as a reason to use radiiofrcquency 
catheter ablation in infants and small &i&en and that thcsc children 
with “medically refractory- arrhythmias have often been treated onl) 
with digotin and propran&. After this statement. the) cite :he report 
from our institution (2). A cursor) rL*xw of that repon would hae 
sbn that in ever? infant and mail &dd who underwent catbcter 
ablatton at our institution, cla5s IC 0T Ill antia+thmic agenl therapy, 
alone or in combination. had failed. Since our +3 of perform4 
surgery for supraventticular arrbyIhmids. we have rescr+ed nonphar- 
macdogic therapy in this age gmup for th@se with failed intensive 
phammco@ii thcmm or a life-threatenir. event (3). We have 
continued to use this pbilosoatry with regard to catheter abiition and 
to date have never performed athcter ablatton in an) infant m whom 
on@ propranolol or dtgoxin therap! had been inekc?zvc. Present&. 
Mta. 
prior use of aspirin resulting in non-Q wave infarction bad hoen 
excluded from ana@is in our smdy. and therefore patemr who 
developd Q wave Infarction ma) be luurciatcd with a k*u incidem of 
aspirin use before mfarction. For thcr rcasom. the benefmal ctfvctr 
of preinfarction angina tinnot be attnhuted to the yor\lMe differcncer 
in the u*e of carthovax-ular medication\ 
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